Table 1.
Baseline patient characteristics of NHL patients aged 55-64 years vs ≥65 years reported to CIBMTR from 2008 to 2015
| Variable | 55-64 years (n = 1183) | ≥65 years (n = 446) | P |
|---|---|---|---|
| Age at HCT, median (range), y | 60 (55-64) | 68 (65-77) | <0.001 |
| Male sex, n (%) | 773 (65) | 303 (68) | 0.32 |
| White, n (%) | 1099 (93) | 421 (94) | 0.28 |
| KPS ≥90, n (%) | 720 (61) | 257 (58) | 0.26 |
| HCT-CI, n (%) | 0.41 | ||
| 0 | 361 (31) | 135 (30) | |
| 1-2 | 367 (31) | 122 (27) | |
| ≥3 | 443 (37) | 185 (42) | |
| Missing | 12 (1) | 4 (<1) | |
| Histology, n (%) | 0.02 | ||
| Follicular lymphoma | 273 (23) | 82 (18) | |
| Diffuse large B-cell lymphoma | 363 (31) | 129 (29) | |
| Mantle cell lymphoma | 257 (22) | 131 (29) | |
| Mature T/NK-cell lymphoma | 237 (20) | 87 (20) | |
| Others | 53 (4) | 17 (4) | |
| Interval from diagnosis to HCT, median (range), mo | 33 (1-386) | 37 (2-322) | 0.59 |
| Disease status prior to HCT, n (%) | 0.68 | ||
| Sensitive | 993 (84) | 384 (86) | |
| Resistant | 179 (15) | 59 (13) | |
| Untreated/unknown | 11 (<1) | 3 (<1) | |
| Prior autologous HCT, n (%) | 451 (38) | 140 (31) | 0.01 |
| Year of HCT, n (%) | 0.18 | ||
| 2008-2010 | 416 (35) | 137 (31) | |
| 2011-2013 | 502 (43) | 195 (44) | |
| 2014-2015 | 265 (22) | 114 (25) | |
| Conditioning regimens, n (%) | 0.35 | ||
| Flu/Bu ± others | 323 (27) | 124 (28) | |
| Flu/CY ± others | 162 (14) | 55 (12) | |
| Flu/CY/TBI ± others | 64 (5) | 30 (7) | |
| Flu/Mel ± others | 311 (26) | 109 (24) | |
| TBI ± others | 41 (3) | 9 (2) | |
| TBI/Flu | 148 (13) | 53 (12) | |
| TLI/ATG | 67 (6) | 36 (8) | |
| Others* | 67 (6) | 30 (7) | |
| ATG/alemtuzumab in conditioning | 323 (27) | 130 (29) | 0.12 |
| Graft source, n (%) | 0.003 | ||
| Bone marrow | 54 (5) | 37 (8) | |
| Peripheral blood | 1129 (95) | 409 (92) | |
| Donor type, n (%) | <0.001 | ||
| MRD | 546 (46) | 156 (35) | |
| MUD | 508 (43) | 241 (54) | |
| mmURD | 129 (11) | 49 (11) | |
| Donor–recipient sex match, n (%) | 0.08 | ||
| Male–male | 502 (42) | 216 (48) | |
| Others | 674 (57) | 226 (51) | |
| Missing | 7 (<1) | 4 (<1) | |
| Donor–recipient CMV status, n (%) | 0.66 | ||
| D−/R+ | 270 (23) | 122 (27) | |
| Others | 744 (63) | 266 (60) | |
| Missing | 169 (14) | 58 (13) | |
| GVHD prophylaxis, n (%) | 0.21 | ||
| CNI + MTX + other(s) except MMF, post-Cy | 572 (48) | 201 (45) | |
| CNI + MMF + other(s) except post-Cy | 403 (34) | 149 (33) | |
| CNI + other(s) except MMF, MTX, post-Cy | 134 (11) | 56 (13) | |
| Others† | 68 (6) | 33 (7) | |
| Missing | 6 (<1) | 7 (2) | |
| Follow-up of survivors, median (range), mo | 48 (4-101) | 48 (6-98) |
ATG, antithymocyte globulin; Bu, busulfan; CMV, cytomegalovirus; CNI, calcineurin inhibitors; Cy, cyclophosphamide; D, donor; Flu, fludarabine; Mel, melphalan; MMF, mycophenolate mofetil; MTX, methotrexate; R, recipient; TBI, total body irradiation; TLI, total lymphoid irradiation.
*
16 beam-like; 56 Flu ± other(s); 25 Mel ± other(s).
†
43 CNI alone; 58 post-Cy ± other(s).